Show simple item record

dc.contributor.authorBennett, Michael J
dc.contributor.authorBalcerek, Matthew
dc.contributor.authorLewis, Edward AD
dc.contributor.authorZhang, Roland LL
dc.contributor.authorBachmeier, Caroline
dc.contributor.authorTey, Siok
dc.contributor.authorFaux, Steven
dc.contributor.authorGirgis, Laila
dc.contributor.authorGreenfield, Jerry R
dc.contributor.authorLazarus, Syndia
dc.date.accessioned2021-10-25T01:39:11Z
dc.date.available2021-10-25T01:39:11Z
dc.date.issued2021
dc.identifier.issn2473-4039en_US
dc.identifier.doi10.1002/jbm4.10557en_US
dc.identifier.urihttp://hdl.handle.net/10072/409440
dc.description.abstractVoriconazole-associated periostitis (VAP) is an underrecognized and unpredictable side effect of long-term voriconazole therapy. We report two cases of VAP occurring in the post-transplant setting: a 68-year-old lung transplant recipient who required ongoing voriconazole therapy, in whom urinary alkalinization was used to promote fluoride excretion and minimize voriconazole-related skeletal toxicity, and a 68-year-old stem-cell transplant recipient with a high voriconazole dose requirement, identified on pharmacogenomic testing to be a CYP2C19 ultrarapid metabolizer, the dominant enzyme in voriconazole metabolism. This is the first reported case of pharmacogenomic profiling in VAP and may explain the variability in individual susceptibility to this uncommon adverse effect. Our findings provide new insights into both the management and underlying pathophysiology of VAP.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.relation.ispartofpagefrome10557en_US
dc.relation.ispartofjournalJBMR PLUSen_US
dc.subject.fieldofresearchClinical sciencesen_US
dc.subject.fieldofresearchcode3202en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsEndocrinology & Metabolismen_US
dc.subject.keywordsMATRIX MINERALIZATION (BONE MATRIX)en_US
dc.subject.keywordsOTHER (DISEASES AND DISORDERS OFen_US
dc.titleVoriconazole-Associated Periostitis: New Insights into Pathophysiology and Managementen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationBennett, MJ; Balcerek, M; Lewis, EAD; Zhang, RLL; Bachmeier, C; Tey, S; Faux, S; Girgis, L; Greenfield, JR; Lazarus, S, Voriconazole-Associated Periostitis: New Insights into Pathophysiology and Management, JBMR PLUS, 2021, pp. e10557en_US
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/en_US
dc.date.updated2021-10-22T01:01:26Z
dc.description.versionVersion of Record (VoR)en_US
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.en_US
gro.rights.copyright© 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,provided the original work is properly cited.en_US
gro.hasfulltextFull Text
gro.griffith.authorTey, Siok


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record